Latest Filings

Issuer Activity

Overview :: ABIOMED, Inc. (OQ:ABMD) [?]
Business Focus: Advanced Medical Equipment & Technology Share on StockTwits
Recent Price for ABMD
USD 26.070 +0.040 (+0.154%)
NSQ Delayed 15 minutes
Aug 28 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
26.130 30.770 150.02 180,707 1,054.88
1-Day Low 52-Week Low Yield Avg. Volume  
25.790 18.150 0.0% NSQ  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 9:56pm ET August 28th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 21/14 Aug 13/14 Rose Eric A Md Direct Ownership Common Stock, $.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Thomas Paul Direct Ownership Common Stock, $.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Termeer Henri A Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Sutter Martin P Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Puhy Dorothy E Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Lataif Louis E Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 9:56pm ET August 28th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 21/14 Aug 13/14 Rose Eric A Md Direct Ownership Common Stock, $.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 21/14 Aug 21/14 Rose Eric A Md Direct Ownership Stock Option (right to buy) Form 3 : Initial Statement of Beneficial Ownership of Securities    
Aug 15/14 Aug 13/14 Thomas Paul Direct Ownership Common Stock, $.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Termeer Henri A Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Sutter Martin P Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Puhy Dorothy E Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Aug 15/14 Aug 13/14 Lataif Louis E Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 7,740  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Key People
Michael R. Minogue
Chairman of the Board, President, Chief Executive Officer
Robert L. Bowen
Chief Financial Officer, Vice President, Treasurer
David M. Weber
Chief Operating Officer
William J. Bolt
Senior Vice President - Global Product Operations
Andrew J. Greenfield
Vice President, General Manager - Global Marketing
Michael G. Howley
Vice President, General Manager - Global Sales and Marketing
Company Contact
Address: 22 CHERRY HILL DR
DANVERS MA 01923
Tel: N/A
Website: www.abiomed.com
IR: investors.abiomed.com
Business Overview
ABIOMED, Inc., is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In April 2014, the Company acquired exclusive license from collaboration partner Opsens Inc. In July 2014, Abiomed Inc acquired ECP Entwicklungsgesellschaft mbH (ECP), medical device company based in Berlin, Germany, and AIS GmbH Aachen Innovative Solutions through ECP.
Financial Overview
For the three months ended 30 June 2014, ABIOMED, Inc. revenues increased 14% to $48.8M. Net loss decreased 1% to $1.7M. Revenues reflect Funded research and development increase from $61K to $151K. Lower net loss reflects Other income (expense), net) increase from $21K (expense) to $11K (income), Investment (expense) income, net increase from $16K to $44K (income).
Employees: 511 as of Mar 31, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $966.07M as of Jun 30, 2014
Annual revenue (TTM): $189.78M as of Jun 30, 2014
EBITDA (TTM): $10.61M as of Jun 30, 2014
Net annual income (TTM): $7.37M as of Jun 30, 2014
Free cash flow (TTM): $24.26M as of Jun 30, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 40,463,481 as of Jul 31, 2014
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Illumina (OQ:ILMN)
Edwards Lifesciences (N:EW)
Cerner (OQ:CERN)